Letσ={σ_(i)|i∈I}be some partition of all primes P and G a finite group.A subgroup H of G is said to beσ-subnormal in G if there exists a subgroup chain H=H_(0)≤H_(1)≤・・・≤Hn=G such that either H_(i−1)is normal i...Letσ={σ_(i)|i∈I}be some partition of all primes P and G a finite group.A subgroup H of G is said to beσ-subnormal in G if there exists a subgroup chain H=H_(0)≤H_(1)≤・・・≤Hn=G such that either H_(i−1)is normal in Hi or Hi/(H_(i−1))Hi is a finiteσj-group for some j∈I for i=1,...,n.We call a finite group G a T_(σ)-group if everyσ-subnormal subgroup is normal in G.In this paper,we analyse the structure of the T_(σ)-groups and give some characterisations of the T_(σ)-groups.展开更多
嵌合抗原受体T细胞(chimeric antigen receptor T cells,CAR-T)的出现使得多发性骨髓瘤(multiple myeloma,MM)患者的治疗进入了一个新的阶段,但大多数患者都难逃原发耐药或疾病复发的不良结局。G蛋白偶联受体C类5组成员D(G protein-coup...嵌合抗原受体T细胞(chimeric antigen receptor T cells,CAR-T)的出现使得多发性骨髓瘤(multiple myeloma,MM)患者的治疗进入了一个新的阶段,但大多数患者都难逃原发耐药或疾病复发的不良结局。G蛋白偶联受体C类5组成员D(G protein-coupled receptor class C group 5 member D,GPRC5D)是目前MM患者的一个有前景的治疗靶点,与GPRC5D CAR-T相关的Ⅰ期临床研究也都显示出较高的反应率和疗效。文章将对现有的靶向GPRC5D CAR-T细胞最新研究进行综述,旨在通过总结讨论目前不同GPRC5D CAR-T细胞治疗复发难治性MM的研究现状,对今后的临床治疗提供更多参考。展开更多
文摘Letσ={σ_(i)|i∈I}be some partition of all primes P and G a finite group.A subgroup H of G is said to beσ-subnormal in G if there exists a subgroup chain H=H_(0)≤H_(1)≤・・・≤Hn=G such that either H_(i−1)is normal in Hi or Hi/(H_(i−1))Hi is a finiteσj-group for some j∈I for i=1,...,n.We call a finite group G a T_(σ)-group if everyσ-subnormal subgroup is normal in G.In this paper,we analyse the structure of the T_(σ)-groups and give some characterisations of the T_(σ)-groups.
文摘嵌合抗原受体T细胞(chimeric antigen receptor T cells,CAR-T)的出现使得多发性骨髓瘤(multiple myeloma,MM)患者的治疗进入了一个新的阶段,但大多数患者都难逃原发耐药或疾病复发的不良结局。G蛋白偶联受体C类5组成员D(G protein-coupled receptor class C group 5 member D,GPRC5D)是目前MM患者的一个有前景的治疗靶点,与GPRC5D CAR-T相关的Ⅰ期临床研究也都显示出较高的反应率和疗效。文章将对现有的靶向GPRC5D CAR-T细胞最新研究进行综述,旨在通过总结讨论目前不同GPRC5D CAR-T细胞治疗复发难治性MM的研究现状,对今后的临床治疗提供更多参考。
